Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol

INTRODUCTION: Patients relapsing within 12 months of platinum-based chemotherapy usually have a poorer response to subsequent treatments. To date, extensive research into the mechanism of resistance to platinum agents in the treatment of ovarian cancer has not resulted in improved responses or longe...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansouri, Anita, McGregor, Naomi, Dunn, Rachel, Dobbie, Sam, Holmes, Jane, Collins, Linda, Nicum, Shibani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813404/
https://www.ncbi.nlm.nih.gov/pubmed/33452192
http://dx.doi.org/10.1136/bmjopen-2020-041463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813404/
https://www.ncbi.nlm.nih.gov/pubmed/33452192
http://dx.doi.org/10.1136/bmjopen-2020-041463

Ejemplares similares